Beneficial effects of aCannabis sativaextract treatment on diabetes‐induced neuropathy and oxidative stress
Authors:
- 25 November 2009
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 23 (12) , 1678-1684
Abstract
Neuropathy is the most common complication of diabetes and it is still considered to be relatively refractory to most of the analgesics. The aim of the present study was to explore the antinociceptive effect of a controlled cannabis extract (eCBD) in attenuating diabetic neuropathic pain. Repeated treatment with cannabis extract significantly relieved mechanical allodynia and restored the physiological thermal pain perception in streptozotocin (STZ)‐induced diabetic rats without affecting hyperglycemia. In addition, the results showed that eCBD increased the reduced glutathione (GSH) content in the liver leading to a restoration of the defence mechanism and significantly decreased the liver lipid peroxidation suggesting that eCBD provides protection against oxidative damage in STZ‐induced diabetes that also strongly contributes to the development of neuropathy. Finally, the nerve growth factor content in the sciatic nerve of diabetic rats was restored to normal following the repeated treatment with eCBD, suggesting that the extract was able to prevent the nerve damage caused by the reduced support of this neurotrophin. These findings highlighted the beneficial effects of cannabis extract treatment in attenuating diabetic neuropathic pain, possibly through a strong antioxidant activity and a specific action upon nerve growth factor. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic painBritish Journal of Pharmacology, 2006
- The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic ratsNeuroscience Letters, 2004
- Repeated treatment with the synthetic cannabinoid WIN 55,212‐2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic painBritish Journal of Pharmacology, 2004
- Protective effect of caffeic acid phenethyl ester (CAPE) on lipid peroxidation and antioxidant enzymes in diabetic rat liverJournal of Biochemical and Molecular Toxicology, 2004
- Tactile directional sensibility and diabetic neuropathyMuscle & Nerve, 2001
- The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painBritish Journal of Pharmacology, 2001
- Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogeneic pancreatic islet transplantationNeuroscience Letters, 1991
- Evaluation of thermal and pain sensitivity in type I diabetic patients.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesiaPain, 1988
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983